Chemotherapy‐induced peripheral neurotoxicity: A critical analysis

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

2000 • 3,785 citations

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2004 • 3,458 citations

World Cancer Report

2003 • 2,484 citations

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

2003 • 2,458 citations

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

2006 • 2,304 citations

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

2009 • 2,086 citations

Strength of Recommendation Taxonomy (SORT): A Patient-Centered Approach to Grading Evidence in the Medical Literature

2004 • 1,376 citations

Guillain–Barré Syndrome

2012 • 1,082 citations

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

2008 • 899 citations

Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy

2013 • 868 citations

Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma

2006 • 749 citations

Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib

2006 • 634 citations

Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies

2008 • 611 citations

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

2006 • 593 citations

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

2008 • 583 citations

How Accurate Is Clinician Reporting of Chemotherapy Adverse Effects? A Comparison With Patient-Reported Symptoms From the Quality-of-Life Questionnaire C30

2004 • 531 citations

Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction

2006 • 498 citations

The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20

2005 • 480 citations

Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force

2010 • 478 citations

Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology

2012 • 451 citations

Multiple measures of axonal excitability: A new approach in clinical testing

2000 • 445 citations

Total neuropathy score

1999 • 423 citations

Guillain-Barr Syndrome

1990 • 422 citations

Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

2002 • 411 citations

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

2005 • 406 citations

Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy

2006 • 391 citations

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

1996 • 387 citations

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

2010 • 371 citations

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity.

1992 • 359 citations

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

1994 • 355 citations

Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council

2001 • 355 citations

Phase I study of oxaliplatin in patients with advanced cancer

1990 • 340 citations

Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy

2007 • 339 citations

Paraneoplastic Neurologic Syndrome in the PNS Euronetwork Database

2010 • 334 citations

Chemotherapy-Induced Neuropathy and Its Association With Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry

2013 • 328 citations

Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

2009 • 327 citations

Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability

2002 • 324 citations

Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study Group

2008 • 321 citations

Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy

2003 • 320 citations

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

2009 • 308 citations

Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum–DNA binding

2006 • 302 citations

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol.

1991 • 293 citations

Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

2004 • 284 citations

Interventions for preventing neuropathy caused by cisplatin and related compounds

2014 • 274 citations

The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons

2000 • 274 citations

Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

2004 • 271 citations

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

2012 • 266 citations

Measuring the side effects of taxane therapy in oncology

2003 • 264 citations

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

2009 • 264 citations

Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

2007 • 264 citations

Chemotherapy-Induced Peripheral Neurotoxicity assessment: A critical revision of the currently available tools

2010 • 259 citations

Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat

2007 • 259 citations

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial

2007 • 256 citations

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

2011 • 250 citations

Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies

2002 • 247 citations

Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies

2008 • 243 citations

Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

2010 • 242 citations

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale

2007 • 235 citations

Peripheral nerve damage associated with administration of taxanes in patients with cancer

2008 • 234 citations

Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer

2007 • 233 citations

Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer

2002 • 231 citations

NCCN Task Force Report: Management of Neuropathy in Cancer

2009 • 231 citations

Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07

2007 • 228 citations

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy

2009 • 218 citations

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial

2010 • 217 citations

Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741

2010 • 214 citations

Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

2010 • 213 citations

Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring

2006 • 209 citations

POEMS syndrome: Update on diagnosis, risk‐stratification, and management

2012 • 206 citations

Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy

2013 • 205 citations

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy

1998 • 203 citations

Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy

2006 • 203 citations

Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients

2007 • 200 citations

Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

2011 • 199 citations

Clinical pattern and associations of oxaliplatin acute neurotoxicity

2012 • 198 citations

Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na _V 1.6-resurgent and persistent current

2012 • 197 citations

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study

2007 • 192 citations

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

2008 • 192 citations

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

2010 • 191 citations

Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening

2005 • 191 citations

Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing.

1997 • 190 citations

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02

2009 • 190 citations

Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy

2008 • 188 citations

Vitamin E neuroprotection for cisplatin neuropathy

2010 • 185 citations

Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility

2011 • 185 citations

Neurotoxicity of Taxol.

1993 • 183 citations

Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study

2009 • 182 citations

Thalidomide-induced neuropathy

2002 • 181 citations

Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

2003 • 179 citations

Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat

2000 • 177 citations

Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia

2010 • 175 citations

An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat

2007 • 170 citations

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial

2010 • 168 citations

Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study

2013 • 165 citations

Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity

2009 • 164 citations

Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

2013 • 162 citations

Impact of Long-Term Serum Platinum Concentrations on Neuro- and Ototoxicity in Cisplatin-Treated Survivors of Testicular Cancer

2011 • 162 citations

Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05

2010 • 161 citations

Paclitaxel drug delivery systems

2013 • 160 citations

Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies

2006 • 158 citations

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

2004 • 156 citations

Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

1999 • 154 citations

Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity

2006 • 153 citations

Putting Evidence Into Practice®: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy

2007 • 152 citations

Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy

2007 • 151 citations

Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors

2009 • 151 citations

Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia

2009 • 149 citations

Long term effects of vincristine on the peripheral nervous system

1993 • 149 citations

Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps

1990 • 146 citations

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases

2011 • 145 citations

Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy

2012 • 144 citations

Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma

2009 • 139 citations

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

2010 • 139 citations

A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results

2006 • 137 citations

Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252

2005 • 136 citations

Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage‐gated sodium channels

2005 • 134 citations

Thalidomide sensory neurotoxicity

2004 • 134 citations

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

2011 • 129 citations

Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes

2007 • 129 citations

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity

2010 • 126 citations

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

2009 • 124 citations

Clinician versus nurse symptom reporting using the National Cancer Institute—Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire

2009 • 121 citations

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

2009 • 120 citations

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study

2006 • 115 citations

Cisplatin-lnduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity

1992 • 114 citations

Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up

2006 • 114 citations

Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics

2011 • 114 citations

Sensory exam with a quantitative tuning fork

2004 • 114 citations

Scale for Chemotherapy-induced Long-term Neurotoxicity (SCIN): Psychometrics, Validation, and Findings in a Large Sample of Testicular Cancer Survivors

2006 • 113 citations

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

2011 • 112 citations

Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas

1994 • 110 citations

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

2009 • 109 citations

Strength and Balance Training for Adults With Peripheral Neuropathy and High Risk of Fall: Current Evidence and Implications for Future Research

2012 • 108 citations

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

2000 • 107 citations

Cisplatin neuropathy: clinical course and neurophysiological findings

1992 • 107 citations

Long-term platinum retention after treatment with cisplatin and oxaliplatin

2008 • 106 citations

Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro

1999 • 105 citations

N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data

2006 • 103 citations

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

2008 • 102 citations

Longitudinal assessment of oxaliplatin-induced neuropathy

2011 • 102 citations

Neurological toxicity of long‐term (>1 yr) thalidomide therapy in patients with multiple myeloma

2005 • 100 citations

Impact of oxaliplatin-induced neuropathy: a patient perspective

2012 • 97 citations

Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study

2007 • 97 citations

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma

2011 • 97 citations

Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

2006 • 96 citations

Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome

2012 • 96 citations

Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer

2008 • 96 citations

Glutamine as a Neuroprotective Agent in High-dose Paclitaxel-induced Peripheral Neuropathy: A Clinical and Electrophysiologic Study

2005 • 94 citations

Immune-mediated neuropathies in myeloma patients treated with bortezomib

2008 • 94 citations

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

2012 • 94 citations

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients

2012 • 93 citations

A prospective surveillance model for physical rehabilitation of women with breast cancer

2012 • 92 citations

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01

2012 • 91 citations

Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.

2009 • 90 citations

Persistent neuropathy after treatment with cisplatin and oxaliplatin

2009 • 90 citations

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis

2001 • 90 citations

Persistent Mobility Disability After Neurotoxic Chemotherapy

2010 • 90 citations

Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties

2010 • 89 citations

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer

2008 • 87 citations

Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?

2007 • 86 citations

Follow-Up Psychophysical Studies in Bortezomib-Related Chemoneuropathy Patients

2011 • 86 citations

The Reliability and Validity of a Modified Total Neuropathy Score-Reduced and Neuropathic Pain Severity Items When Used to Measure Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxanes and Platinums

2010 • 84 citations

Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study

1999 • 82 citations

Therapeutic Angiogenesis Inhibits or Rescues Chemotherapy-induced Peripheral Neuropathy: Taxol- and Thalidomide-induced Injury of Vasa Nervorum is Ameliorated by VEGF

2006 • 81 citations

Polymorphic markers associated with severe oxaliplatin‐induced, chronic peripheral neuropathy in colon cancer patients

2011 • 78 citations

Limited Access Trial Using Amifostine for Protection Against Cisplatin- and Three-Hour Paclitaxel–Induced Neurotoxicity: A Phase II Study of the Gynecologic Oncology Group

2003 • 78 citations

Neuropathy and paraproteins: review of a complex association

2011 • 77 citations

Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration

2006 • 77 citations

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer

2011 • 75 citations

Thalidomide-induced neuropathy: A ganglionopathy?

2003 • 75 citations

Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients

2011 • 74 citations

Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial

2010 • 72 citations

Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons

2009 • 72 citations

Permeation of proteins from the blood into peripheral nerves and ganglia

1994 • 71 citations

An Update on Monoclonal Gammopathy and Neuropathy

2011 • 70 citations

Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale

2011 • 69 citations

Evidence for direct axonal toxicity in vincristine neuropathy

2006 • 65 citations

Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features

2003 • 61 citations

Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy

1989 • 60 citations

Role of a pre‐existing neuropathy on the course of bortezomib‐induced peripheral neurotoxicity

2008 • 58 citations

Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life‐threatening vincristine neurotoxicity

2001 • 58 citations

The Neuropathies of Waldenström's Macroglobulinemia (WM) and IgM-MGUS

2011 • 56 citations

Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation

2012 • 56 citations

Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma

2000 • 56 citations

Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin

2007 • 54 citations

Late Non-Neoplastic Events in Patients with Aggressive Non-Hodgkin's Lymphoma in Four Randomized European Organisation for Research and Treatment of Cancer Trials

2005 • 53 citations

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

2011 • 52 citations

Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients

2008 • 51 citations

Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis

2011 • 48 citations

Treatment for paraneoplastic neuropathies

2012 • 46 citations

Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma

2010 • 44 citations

Thalidomide maintenance following high‐dose therapy in multiple myeloma: a UK myeloma forum phase 2 study

2007 • 44 citations

Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia

2010 • 44 citations

Peripheral Neurotoxicity of Weekly Paclitaxel Chemotherapy: A Schedule or a Dose Issue?

2007 • 41 citations

Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS)

2013 • 40 citations

Vincristine-induced autonomic neuropathy.

1975 • 40 citations

Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis

2012 • 40 citations

Thalidomide and sensory neurotoxicity: a neurophysiological study

2008 • 40 citations

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

2012 • 38 citations

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity

2002 • 37 citations

Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184

2010 • 37 citations

Guillain-Barre Syndrome

1997 • 37 citations

Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h

2003 • 36 citations

Features and Risk Factors of Peripheral Neuropathy During Treatment with Bortezomib for Advanced Multiple Myeloma

2008 • 34 citations

Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel

2011 • 30 citations

Bortezomib-induced severe autonomic neuropathy

2012 • 29 citations

Vincristine‐induced acute neurotoxicity versus Guillain–Barré syndrome: a diagnostic dilemma

2007 • 28 citations

Reintroduction of Oxaliplatin: A Viable Approach to the Long-Term Management of Metastatic Colorectal Cancer

2010 • 26 citations

Vincristine-Related Neuropathy Versus Acute Inflammatory Demyelinating Polyradiculoneuropathy in Children With Acute Lymphoblastic Leukemia

2012 • 26 citations

Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer

2011 • 25 citations

A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer

2005 • 24 citations

A randomized phase 2 trial comparing 3‐hour versus 96‐hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer

2010 • 24 citations

Patient-Reported Outcomes in Chemotherapy-Induced Peripheral Neuropathy: A Review

2010 • 23 citations

Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis

2011 • 22 citations

Acute motor and sensory axonal neuropathy in Burkitt‐like lymphoma

2006 • 22 citations

GUILLAIN-BARRÉ SYNDROME IN A CHILD WITH ACUTE LYMPHOBLASTIC LEUKEMIA

2001 • 22 citations

Low‐dose vs. high‐dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

2011 • 19 citations

Paraneoplastic disorders of the peripheral nervous system

2013 • 16 citations

Phase III Randomized, Placebo(Pl)-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium (CaMg) to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (sNT), N08CB: an Alliance for Clinical Trials in Oncology Study1

2013 • 15 citations

Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB: An alliance for clinical trials in oncology study.

2013 • 15 citations

Acute onset flaccid quadriparesis in pediatric non-Hodgkin lymphoma: Vincristine induced or Guillain-Barré syndrome?

2010 • 15 citations

Low-Dose Thalidomide for Multiple Myeloma: Interim Analysis of a Compassionate Use Program

2004 • 12 citations

S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer.

2013 • 11 citations

Deleted Work

1955 • 0 citations